Digital pathology is transforming the industry. Its extraordinary impact now spans modalities, therapeutic areas, and applications, making it nearly impossible to capture its full scope. With momentum continuing to build, breakthroughs like Roche and AstraZeneca’s first AI-driven CDx approval are pushing the field into an exciting new era. Yet, to fully unlock the potential of this revolutionary technology, critical challenges must be addressed. From implementation and standardization to reimbursement and adoption, the field must come together to ask the right questions, and find the best answers, that will ensure digital pathology delivers on its promise: improving patient stratification, enabling real-time data insights, and helping bring the right therapies to the right patients with maximum impact.